Prevention & lipidsResearch article
Childhood Screening for Familial Hypercholesterolemia
- Narrative review
Authors' conclusion
Incorporating these concepts into existing evidence pathways allows the inclusion of surrogate clinical trial outcomes (low-density lipoprotein cholesterol reduction and atherosclerosis regression) and observational data on medication safety, strengthening the evidence for pediatric screening for FH.
Study context
- Population
- Children; screening for familial hypercholesterolemia (FH)
Main finding
As reported in the abstract
Strength of evidence for pediatric FH screening
- Incorporating FH as a tier 1 genetic condition and LDL-C as causal for atherosclerosis and CHD allows inclusion of surrogate trial outcomes (LDL-C reduction, atherosclerosis regression) and observational medication-safety data, strengthening the evidence for pediatric FH screening
Original publication
Childhood Screening for Familial Hypercholesterolemia. J Am Coll Cardiol. Published 10 October 2023. doi:10.1016/j.jacc.2023.07.028
Summarised from the published abstract; every number is checked against it